Nuvation Bio NUVB Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -105%+5,658pp | -338.7%— | -871%— | -1,564.9%— | -5,762.8%— | |
| Net margin | -102.1%+5,432pp | -325.3%— | -813.1%— | -1,413.4%— | -5,534.2%— | |
| Returns | ||||||
| Return on equity | -39.5%+80.2pp | -53.2%+53.1pp | -52.5%+43.0pp | -64.4%+51.4pp | -119.7%-109pp | |
| Return on invested capital | -47.4%+86.1pp | -67%+51.1pp | -60.6%+43.4pp | -106.9%+24.9pp | -133.5%-118pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×+0.2× | 0.1×+0.1× | 0×0.0× | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 7.4×-1.6× | 7×-2.1× | 8.5×-1.1× | 9.4×-2.1× | 9×-29.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.2× | 0.2×+0.2× | 0.2×+0.2× | 0.2×+0.1× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $0.85-31.7% | $0.90-48.1% | $0.95-48.2% | $1.09+4.1% | $1.24-54.3% | |
| Valuation | ||||||
| Market capitalization | $1.49B+150% | $3.07B+243% | $1.27B+126% | $697.54M+9.1% | $596.07M-25.2% | |
| Price / sales | 10.4×-44.0× | 48.8×— | 47.3×— | 48.6×— | 54.4×— | |
| Price / book | 4.7×+3.2× | 10×+8.1× | 3.9×+2.8× | 1.9×-0.6× | 1.4×+0.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nuvation Bio's profit margins?
- Nuvation Bio (NUVB) runs a 54.3% gross margin and a -105.0% operating margin, with a -102.1% net margin.
- Where do Nuvation Bio's ratios come from?
- Every ratio is computed from Nuvation Bio's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
